In brief: Because ibogaine carries a documented cardiac risk profile, choosing an ibogaine treatment center is fundamentally a medical-safety decision, not a lifestyle one. This checklist walks through the specific infrastructure — screening, monitoring, staffing, and pharmaceutical sourcing — that separates a responsibly run program from one that is not, and the red flags that should end a conversation. Educational only; not medical advice.
1. EKG and QTc Screening — Non-Negotiable
Any ibogaine treatment center worth considering should require a 12-lead ECG with a measured QTc interval before dosing, full stop. Ibogaine and its active metabolite noribogaine block the hERG potassium channel, prolonging cardiac repolarization and creating a risk of the arrhythmia torsades de pointes — a risk documented in case series of ibogaine-associated fatalities. A center that cannot describe this screening step clearly, or treats it as optional, has already disqualified itself.
Ask specifically: is the ECG performed on site, by whom, and is it reviewed by a physician before dosing is approved — not simply filed. Ask what QTc threshold results in exclusion from dosing, and whether the center also checks electrolytes (potassium, magnesium) and screens medication and supplement history for QT-prolonging drugs and CYP2D6 interactions. Our detailed breakdown of this process is in the ibogaine cardiac safety screening guide, and it is the first thing worth reading before evaluating any ibogaine treatment quote.
2. An On-Site Physician, Named and Credentialed
"Medically supervised" is a phrase used loosely across this industry, and it is worth pressing on specifically. A credible ibogaine treatment center should be able to name its supervising physician, describe their credentials, and confirm they are physically present — not merely reachable by phone — during screening, dosing, and the monitoring window that follows.
Cardiac events related to ibogaine, when they occur, can develop over minutes, not hours. A physician who has to be called in after symptoms appear has already lost time that may matter. Ask how many physicians and nurses are on shift during a dosing day, what their emergency-response training includes, and what happens in the specific scenario of a QT-related arrhythmia — the answer should be immediate and specific, not general reassurance.
A named, checkable physician and a named, checkable regulator are two separate but related tests. Reputable centers, including our own program described on the ibogaine treatment page, should pass both without hesitation.
3. Continuous Telemetry During and After Dosing
Screening tells you a client was safe to dose at one point in time. Continuous cardiac telemetry — real-time ECG monitoring throughout the dosing session and into the noribogaine tail that follows — tells you whether they remain safe hour by hour as the substance acts on the body. This is a meaningfully different and more expensive standard than periodic vital-sign checks, and it is one of the clearest ways to distinguish a serious clinical program from one cutting corners.
Ask exactly how long telemetry monitoring continues after the acute visionary phase ends. Because noribogaine has a considerably longer half-life than ibogaine itself, cardiac risk does not end when the visionary effects do — monitoring that stops too early is a meaningful gap, not a minor one. The full hour-by-hour structure of a properly run dosing day and the tail that follows is described in how ibogaine treatment works.
Also ask what emergency equipment is physically in the room — a defibrillator, resuscitation medications, oxygen, and IV access should be immediately available, not stored elsewhere in the building.
4. Pharmaceutical-Grade Ibogaine, Not Unstandardized Extract
A center's sourcing matters as much as its monitoring. Pharmaceutical-grade ibogaine hydrochloride has known, laboratory-tested purity and alkaloid concentration, which allows a physician to calculate a dose with some predictability. Crude iboga root bark or unstandardized extracts, by contrast, carry variable and sometimes unknown total alkaloid content — meaning the same measured weight can deliver meaningfully different amounts of active compound from one batch to the next.
Given that ibogaine's principal risk is dose-related cardiac toxicity, that variability is not a minor quality issue — it directly undermines a physician's ability to dose safely. Ask a prospective center what form of ibogaine they use, whether it is tested for purity and alkaloid content by an independent lab, and whether dosing is calculated by body weight under physician oversight. A center that cannot answer this clearly is asking you to trust a variable it has not measured. Background on ibogaine's pharmacology is covered in what ibogaine is.
5. Medication Tapering, Done Under Supervision — Never Abruptly
Many clients arrive at an ibogaine treatment center on medications that either interact with ibogaine or need to be adjusted before dosing — opioids, benzodiazepines, SSRIs, and other CYP2D6-metabolized or QT-affecting drugs among them. A responsible center manages this as a supervised medical taper, timed individually, rather than instructing clients to stop everything before arrival or, worse, not addressing it at all.
Abrupt discontinuation of benzodiazepines carries a genuine seizure risk and must be physician-managed regardless of what treatment follows. Ask a prospective center how they handle a client who arrives on an SSRI, a benzodiazepine, or methadone or buprenorphine specifically — the answer should describe an individualized medical plan, not a blanket policy. Our comparison of ibogaine against a maintenance-medication approach is covered in ibogaine vs. methadone.
6. Licensing You Can Actually Verify
Because ibogaine is not an approved medication in the United States, most legitimate clinical programs operate in jurisdictions where it is legal to administer, most commonly Mexico. That makes the identity of the regulator especially important: a facility should be able to name the specific health authority that licenses it, and that authority should be independently checkable rather than a name you only encounter on the center's own website.
Sanctuary Tulum is licensed by COFEPRIS, Mexico's federal health regulator, and describes its clinical oversight on the medical review board page. When comparing centers, ask for the specific regulator, the license type, and how long the facility has held it — vague claims of being "licensed" without a named authority are a meaningful red flag, not a technicality.
7. A Concrete Aftercare Plan, Not a Brochure Line
The clinical literature on addiction treatment consistently associates durable outcomes with continuity of care after an intensive intervention, and ibogaine is no exception. A single dosing session, however well-monitored, is not designed to be a standalone, permanent solution — the period afterward is when the groundwork for lasting change actually gets built.
A serious ibogaine treatment center should offer a concrete discharge plan before the client ever arrives: a named outpatient provider or therapist, scheduled follow-up check-ins over the weeks after dosing, and clear guidance on any remaining medication taper. Ask exactly what is included in aftercare, for how long, and at what additional cost — "we support you afterward" is not an answer; a schedule and a named point of contact is. Our overview of ibogaine's documented role in addiction treatment is on the ibogaine for addiction page.
Group Size, Staffing Ratios, and Facility Environment
Beyond the seven areas above, the physical environment and staffing ratio of an ibogaine treatment center are worth asking about directly, because they affect how quickly a problem is noticed and how promptly it can be addressed. A center running several dosing sessions simultaneously with a thin nursing staff is structurally different from one that dedicates a full clinical team to a single client during their dosing day, even if both describe themselves as "medically supervised."
Ask how many clients are typically dosed on the same day, how many nurses and physicians are on shift relative to that number, and whether telemetry is monitored centrally by staff dedicated to that task or checked periodically by someone also managing other responsibilities. A smaller, more deliberately paced program is not automatically safer, but a program that cannot answer these staffing questions with specific numbers is asking for trust it has not earned with detail.
It is also worth asking what the facility's plan is for a medical emergency that exceeds on-site capability — specifically, transfer time to the nearest hospital equipped for cardiac emergencies, and whether that route has been tested rather than assumed. A center located a long drive from adequate emergency care carries a different risk profile than one with a fast, established transfer relationship, regardless of how well-equipped its own facility is.
Red Flags Worth Walking Away From
A handful of warning signs recur across less careful operators in this space, and any one of them is reason enough to keep looking elsewhere.
- No mention of ECG or QTc screening, or a vague answer when asked directly.
- An "on-call" physician instead of one physically present during screening and dosing.
- No continuous cardiac telemetry during dosing and the days that follow.
- Unclear or unnamed licensing authority, or reluctance to name one.
- Pressure to abruptly stop psychiatric medication or benzodiazepines before arrival without a supervised plan.
- No description of on-site emergency equipment or a clear emergency protocol.
- Guarantees of a cure or a specific success rate — a claim the honest clinical literature does not support.
- No concrete aftercare plan beyond the dosing experience itself.
None of these signs alone always means a center is unsafe, but a pattern of several is a reliable warning. The strongest protection available to anyone evaluating this decision is simply asking these questions directly, in writing, before committing — a program with nothing to hide will answer plainly, with names and numbers rather than adjectives.
Putting the Checklist to Use
Used together, these seven areas — cardiac screening, on-site physician, continuous telemetry, pharmaceutical-grade sourcing, supervised medication tapering, verifiable licensing, and concrete aftercare — give a much more reliable picture of an ibogaine treatment center than any photograph of a facility or unverifiable testimonial ever will. For a walk-through of what a well-run program looks like once these boxes are checked, see how ibogaine treatment works, and for a comparison of programs against these standards, see our guide to the best ibogaine treatment center options, or review our own ibogaine treatment program.
Editorial note: This article is educational and does not constitute medical advice, diagnosis, or a treatment recommendation, and makes no claims about outcomes for any individual. Ibogaine carries documented cardiac risk and is not legal or approved as a medication in the United States. Anyone considering ibogaine treatment should consult a qualified physician about their own medical history first.
References
- Alper KR, Stajić M, Gill JR. Fatalities Temporally Associated with the Ingestion of Ibogaine. Journal of Forensic Sciences. PubMed.
- Litjens RPW, Brunt TM. How Toxic Is Ibogaine? Clinical Toxicology, PMC.
- Review of ibogaine pharmacology, hERG channel blockade, and QT-interval prolongation mechanisms. PMC.
- Clinical review on benzodiazepine withdrawal, seizure risk, and the contraindication of abrupt discontinuation. PubMed.
- Observational research on ibogaine treatment for opioid withdrawal and post-treatment outcomes. PMC.
- National Institutes of Health / NCBI Bookshelf. Clinical guidance on withdrawal management and medically supervised detoxification.
- Clinical and pharmacological research on noribogaine's extended half-life and cardiac considerations. PubMed.
- COFEPRIS (Comisión Federal para la Protección contra Riesgos Sanitarios) — Mexico's federal health regulatory agency.
